PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

(2018) M. Catherine Pietanza et al.   JOURNAL OF CLINICAL ONCOLOGY

Wild-type and mutated IDH1/2 enzymes and therapy responses

(2018) Remco J. Molenaar et al.   ONCOGENE

Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation

(2018) Paul Lesueur et al.   Scientific Reports

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

(2017) Sani H. Kizilbash et al.   MOLECULAR CANCER THERAPEUTICS

Replication Fork Reversal: Players and Guardians

(2017) Annabel Quinet et al.   MOLECULAR CELL

Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers

(2017) Angelo Taglialatela et al.   MOLECULAR CELL

PARPi focus the spotlight on replication fork protection in cancer

(2017) Katharina Schlacher   NATURE CELL BIOLOGY

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

(2017) Jann N Sarkaria et al.   NEURO-ONCOLOGY

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

(2016) Aparajitha Vaidyanathan et al.   BRITISH JOURNAL OF CANCER

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

(2016) Benjamin H. Lok et al.   CLINICAL CANCER RESEARCH

Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

(2016) Jessica S. Brown et al.   Cancer Discovery

Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

(2016) Gaspar J. Kitange et al.   Cell Reports

Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA

(2016) Sarah L. Daniels et al.   PLoS One

BRCA1 germline mutation and glioblastoma development: report of cases

(2015) Meriem Boukerroucha et al.   BMC CANCER

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion

(2015) Kensuke Tateishi et al.   CANCER CELL

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma

(2015) J. L. Pokorny et al.   CLINICAL CANCER RESEARCH

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma

(2015) S.-W. Tang et al.   CLINICAL CANCER RESEARCH

SLFN11 inhibits checkpoint maintenance and homologous recombination repair

(2015) Y. Mu et al.   EMBO REPORTS

Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

(2015) Shiv K. Gupta et al.   JNCI-Journal of the National Cancer Institute

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide

(2015) O. Erice et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

(2015) K. E. Parrish et al.   MOLECULAR CANCER THERAPEUTICS

Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma

(2015) Rajneet K. Oberoi et al.   NEURO-ONCOLOGY

Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma

(2015) C. M. Becker et al.   NEURO-ONCOLOGY

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

(2015) Vanesa Nogales et al.   Oncotarget

Delineation ofMGMTHypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma

(2015) Shiv K. Gupta et al.   JNCI-Journal of the National Cancer Institute

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

(2015) Sonja J. Gill et al.   PLoS One

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan

(2014) Li Tian et al.   ANTI-CANCER DRUGS

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide

(2014) Lucio Tentori et al.   BMC CANCER

Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

(2014) S. K. Gupta et al.   CLINICAL CANCER RESEARCH

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

(2014) F. Lin et al.   CLINICAL CANCER RESEARCH

Characterizing DNA methylation alterations from The Cancer Genome Atlas

(2014) Daniel J. Weisenberger   JOURNAL OF CLINICAL INVESTIGATION

Genome-wide transcriptome profiling of homologous recombination DNA repair

(2014) Guang Peng et al.   Nature Communications

IDH1 and IDH2 Mutations in Gliomas

(2013) Adam L. Cohen et al.   Current Neurology and Neuroscience Reports

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition

(2013) M. L. Bailey et al.   MOLECULAR CANCER THERAPEUTICS

Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study

(2013) D. H. Pafundi et al.   NEURO-ONCOLOGY

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

(2013) Lara Barazzuol et al.   Radiation Oncology

Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ

(2013) Kyeung Min Joo et al.   Cell Reports

A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2

(2012) Katharina Schlacher et al.   CANCER CELL

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

(2012) S. Ying et al.   CANCER RESEARCH

Active Efflux of Dasatinib from the Brain Limits Efficacy against Murine Glioblastoma: Broad Implications for the Clinical Use of Molecularly Targeted Agents

(2012) S. Agarwal et al.   MOLECULAR CANCER THERAPEUTICS

BRCA1 and MicroRNAs: Emerging networks and potential therapeutic targets

(2012) Suhwan Chang et al.   MOLECULES AND CELLS

The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells

(2012) Tor-Christian Aase Johannessen et al.   NEURO-ONCOLOGY

Biomarkers of PARP inhibitor sensitivity

(2011) Nicholas C. Turner et al.   BREAST CANCER RESEARCH AND TREATMENT

The role of PARP in DNA repair and its therapeutic exploitation

(2011) M Javle et al.   BRITISH JOURNAL OF CANCER

Improving Patient Outcomes in Glioblastoma Through Integration of Recent Data: Introduction

(2011) Mark R. Gilbert   SEMINARS IN ONCOLOGY

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

(2009) J. P. Palma et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

(2009) M. J. Clarke et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

(2008) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks

(2008) X. Liu et al.   MOLECULAR CANCER RESEARCH

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY